Terns Pharmaceuticals (NASDAQ:TERN) Raised to Hold at Wall Street Zen

Terns Pharmaceuticals (NASDAQ:TERN) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

A number of other equities analysts have also commented on the company. William Blair raised Terns Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research note on Monday, November 3rd. Jefferies Financial Group reiterated a “buy” rating and set a $70.00 price target on shares of Terns Pharmaceuticals in a research report on Wednesday, December 10th. Truist Financial increased their price objective on shares of Terns Pharmaceuticals from $35.00 to $56.00 and gave the stock a “buy” rating in a report on Tuesday, December 9th. BMO Capital Markets boosted their target price on shares of Terns Pharmaceuticals from $35.00 to $54.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 9th. Finally, UBS Group upgraded shares of Terns Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, December 4th. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $55.80.

Terns Pharmaceuticals Stock Up 0.1%

Shares of Terns Pharmaceuticals stock opened at $37.79 on Friday. Terns Pharmaceuticals has a 12-month low of $1.87 and a 12-month high of $48.26. The stock has a market capitalization of $3.92 billion, a P/E ratio of -36.69 and a beta of -0.28. The company has a 50-day simple moving average of $38.73 and a 200 day simple moving average of $21.36.

Insider Activity

In related news, insider Emil Kuriakose sold 1,155 shares of the stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $38.57, for a total value of $44,548.35. Following the sale, the insider directly owned 50,365 shares in the company, valued at $1,942,578.05. This trade represents a 2.24% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Amy L. Burroughs sold 71,339 shares of Terns Pharmaceuticals stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $38.10, for a total transaction of $2,718,015.90. Following the transaction, the chief executive officer directly owned 138,976 shares in the company, valued at $5,294,985.60. The trade was a 33.92% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 141,243 shares of company stock worth $5,311,090 in the last three months. Insiders own 1.50% of the company’s stock.

Institutional Investors Weigh In On Terns Pharmaceuticals

Several hedge funds have recently bought and sold shares of the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in shares of Terns Pharmaceuticals in the 4th quarter valued at $25,000. GAMMA Investing LLC lifted its holdings in Terns Pharmaceuticals by 762.4% during the fourth quarter. GAMMA Investing LLC now owns 871 shares of the company’s stock worth $35,000 after acquiring an additional 770 shares in the last quarter. EverSource Wealth Advisors LLC grew its stake in Terns Pharmaceuticals by 61.6% in the fourth quarter. EverSource Wealth Advisors LLC now owns 2,207 shares of the company’s stock valued at $89,000 after acquiring an additional 841 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its stake in Terns Pharmaceuticals by 29.4% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,377 shares of the company’s stock valued at $177,000 after acquiring an additional 994 shares during the period. Finally, iA Global Asset Management Inc. bought a new stake in shares of Terns Pharmaceuticals in the fourth quarter worth about $43,000. 98.26% of the stock is currently owned by institutional investors and hedge funds.

About Terns Pharmaceuticals

Terns Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing oral small‐molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company’s research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies.

The company’s pipeline features several candidates in various stages of preclinical and clinical evaluation.